The approval is relatively small: The drug, Elevidys, is indicated for 4- and 5-year-olds “with a confirmed mutation in the DMD gene who do not have a pre-existing medical reason preventing treatment with this therapy,” the FDA said.
Elevidys is a single intravenous dose that was granted accelerated approval after a clinical trial found the drug increased a protein present in normal muscle cells among patients aged 4 and 5. It will cost $3.2 million, its drugmaker Sarepta Therapeutics said June 22.
Most therapies for DMD focus on symptoms of the disease that affects about 1 in every 3,300 males and kills most patients in their 20s or 30s, but Sarepta’s newly approved medication is the first to target the condition’s genetic cause.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
